SCHEMBL728928

SCHEMBL728928

COc1ccc2c(Nc3c(C)cncc3C)cc(=O)[nH]c2c1OCCCn1ccnc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
CYP19A1 P11511 3/20 0.41
SRC P12931 1/20 0.40
ALDH1A1 P00352 4/20 0.40
NQO2 P16083 1/20 0.40
MAPK1 P28482 2/20 0.40
TP53 P04637 1/20 0.40
GAA P10253 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HTT P42858 1/20 0.40
KDM4E B2RXH2 2/20 0.39
LMNA P02545 2/20 0.39
QPCT Q16769 1/20 0.39
USP2 O75604 1/20 0.39
ALOX15 P16050 1/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL731038 0.97 KMT2A (0.43) MEN1KMT2ACYP19A1ALDH1A1NQO2
SCHEMBL730891 0.97 MEN1 (0.45) MEN1KMT2ACYP19A1ALDH1A1MAPK1
SCHEMBL729366 0.97 MEN1 (0.45) MEN1KMT2ACYP19A1ALDH1A1MAPK1
SCHEMBL728643 0.91 PDE4B (0.49) MEN1KMT2ASRCALDH1A1MAPK1
SCHEMBL730897 0.84 NQO2 (0.46) CYP19A1NQO2MAPK1
SCHEMBL730965 0.83 CYP19A1 (0.45) CYP19A1NQO2MAPK1
SCHEMBL723600 0.83 PDE4B (0.47) CYP19A1NQO2MAPK1
SCHEMBL728717 0.83 PDE4B (0.46) CYP19A1NQO2MAPK1
SCHEMBL726599 0.83 PDE4B (0.46) CYP19A1NQO2MAPK1
SCHEMBL731065 0.82 PDE4B (0.48) CYP19A1NQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2467376-A1 BICYCLIC HETEROARYL INHIBITORS OF PDE4 Kalypsys, Inc. (US) 2012-06-27 EP claimed
WO-2011093924-A1 BICYCLIC HETEROARYL INHIBITORS OF PDE4 KALYPSYS, INC (US) 2011-08-04 WO claimed
US-20130045975-A1 BICYCLIC HETEROARYL INHIBITORS OF PDE4 KALYPSYS, INC. (US) 2013-02-21 US disclosed
US-8138205-B2 Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 KALYPSYS, INC. (US) 2012-03-20 US disclosed
US-20100081646-A1 BICYCLIC HETEROARYL INHIBITORS OF PDE4 KALYPSYS, INC. (US) 2010-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130045975-A1 BICYCLIC HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C MEN1 4354/4885KMT2A 3640/4885CYP19A1 1277/4885
US-20100081646-A1 BICYCLIC HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C MEN1 4354/4885KMT2A 3640/4885CYP19A1 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.